Technical Analysis for TRIL - Trillium Therapeutics Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| See historical TRIL trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| NR7-2 | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Stochastic Buy Signal | Bullish | 2.36% | |
| NR7 | Range Contraction | 2.36% | |
| Lower Bollinger Band Walk | Weakness | 2.36% | |
| Wide Bands | Range Expansion | 2.36% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/10/2019
- Sector: Healthcare
- Industry: Biotechnology
Trillium Therapeutics Inc. is an immuno-oncology company developing innovative
therapies for the treatment of cancer. The Company has two premier preclinical
programs, SIRPaFc and a CD200 monoclonal antibody (mAb), which target two key
immunoregulatory pathways that tumor cells exploit to evade the host immune system.
SIRPaFc is an antibody-like fusion protein that blocks the activity of CD47, a molecule
that is upregulated on tumor cells in acute myeloid leukemia (AML) and numerous other
malignancies. The CD200 mAb is a fully human monoclonal antibody that blocks the
activity of CD200, an immunosuppressive molecule that is overexpressed by many
hematopoietic and solid tumors.
For more information visit: www.trilliumtherapeutics.com
Medicine Cancer Medical Specialties Immunology Treatment Of Cancer Immune System Cancer Immunotherapy Tumor Acute Myeloid Leukemia Monoclonal Antibody Antibody Drug Conjugates Cancer Research CD47
Medicine Cancer Medical Specialties Immunology Treatment Of Cancer Immune System Cancer Immunotherapy Tumor Acute Myeloid Leukemia Monoclonal Antibody Antibody Drug Conjugates Cancer Research CD47
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more TRIL news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 6.75 |
| 52 Week Low | 0.24 |
| Average Volume | 263,845 |
| 200-Day Moving Average | 1.1028 |
| 50-Day Moving Average | 0.3403 |
| 20-Day Moving Average | 0.3201 |
| 10-Day Moving Average | 0.2961 |
| Average True Range | 0.0306 |
| ADX | 22.07 |
| +DI | 12.0552 |
| -DI | 24.1339 |
| Chandelier Exit (Long, 3 ATRs ) | 0.2882 |
| Chandelier Exit (Short, 3 ATRs ) | 0.3318 |
| Upper Bollinger Band | 0.3849 |
| Lower Bollinger Band | 0.2553 |
| Percent B (%b) | 0.24 |
| BandWidth | 40.487348 |
| MACD Line | -0.0222 |
| MACD Signal Line | -0.0177 |
| MACD Histogram | -0.0045 |
| Fundamentals | Value |
|---|---|
| Market Cap | 3.09 Million |
| Num Shares | 10.8 Million |
| EPS | -4.08 |
| Price-to-Earnings (P/E) Ratio | -0.07 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 4.22 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.32 | ||||
| Resistance 3 (R3) | 0.32 | 0.31 | 0.32 | ||
| Resistance 2 (R2) | 0.31 | 0.30 | 0.31 | 0.31 | |
| Resistance 1 (R1) | 0.30 | 0.30 | 0.29 | 0.30 | 0.31 |
| Pivot Point | 0.29 | 0.29 | 0.28 | 0.29 | 0.29 |
| Support 1 (S1) | 0.27 | 0.28 | 0.27 | 0.27 | 0.26 |
| Support 2 (S2) | 0.26 | 0.27 | 0.26 | 0.26 | |
| Support 3 (S3) | 0.25 | 0.26 | 0.26 | ||
| Support 4 (S4) | 0.25 |
